

**Press Release**

**For Immediate Release**

**Granules India reports Income from operations at INR 850 Cr up 16% YoY,  
EBITDA at INR 201 Cr, EBITDA Margin at 24%  
PAT at INR 120 Cr, up 8% YoY**

**Hyderabad, 27<sup>th</sup> July 2021:** Granules India Ltd., a vertically integrated pharmaceutical company, today announced its financial results for the quarter ended June 30, 2021.

**Q1FY22 Financial Highlights (All numbers in INR Cr except Margins)**

<b>CONSOLIDATED FINANCIALS</b>	<b>Q1FY22</b>	<b>Q1FY21</b>	<b>Growth (YoY)</b>
Income from Operations	850	736	16%
Operating Profit	201	184	10%
Operating Profit Margin	24%	25%	
PAT	120	111	8%
Net Profit Margin	14%	15%	

**Financial and Business Highlights for Q1FY22**

- Income from operations up 16% YoY, despite challenges faced by shortage of raw materials, lower utilization capacities especially in Paracetamol and logistic disruptions. Non receipt of MEIS benefit also impacted the total income. However, the growth was driven by new launches and increased market share for existing products.
- EBITDA for the quarter stood at INR 201 Cr, up 10% YoY due to sales increase, mainly in North America.
- PAT for the quarter stood at INR 120 Cr, up 8% YoY.
- During the quarter, we filed one ANDA, two EU dossiers, one UK dossier and one South African dossier. We received one ANDA approval and launched one ANDA in the US
- Pharmaceutical Formulation Intermediates (PFI) segment grew 25% YoY, Active Pharmaceutical Ingredients (API) segment grew 5% YoY and Finished Dosage (FD) grew 18% YoY in terms of value.
- The Board of Directors has declared its first interim dividend of 25 paise per equity share of INR 1/- each.

**Commenting on the results, Mr. Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India Limited said,** “The last quarter was full of learnings and challenges both in terms of business and battling the pandemic. Business was temporarily impacted, and actions were taken to get it back on track. This testing time had given us an opportunity to think and plan to empower our future in a sustainable and reliable manner. I am happy that we are getting over these difficult times and becoming stronger to carry out our aspirations. We are focusing on making our growth strategy more robust, while taking a hard look on our product pipeline which is our growth engine. While remaining confident of our sustainable growth, efforts will be continued to formalise and follow an orbit changing strategy. I remain confident of our future sustainable growth.”

**Segmental, Molecule and Geographical Mix for Q1 FY22 (All numbers in INR Cr)**

Segmental Mix	Q1FY22	Q1FY21
FD	454	386
PFI	172	138
API	224	212

Geographical Mix	Q1FY22	Q1FY21
North America	451	381
Europe	143	141
Latin America	92	86
India	118	84
ROW	46	44

Molecule Mix %	Q1FY22	Q1FY21
Paracetamol	36%	31%
Metformin	27%	23%
Ibuprofen	15%	24%
Guaifenesin	1%	4%
Methocarbamol	3%	4%
Others	18%	14%



**About Granules India Ltd. (BSE: 532482, NSE: GRANULES)**

Granules India Limited, incorporated in 1991 is a vertically integrated fast growing Indian pharmaceutical company headquartered at Hyderabad with best in class facilities and commitment to operational excellence, quality, and customer service. We are among the few pharmaceutical companies in the world to be present in the manufacturing of entire value chain – from Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages (FDs). Our products are being distributed to over 300+ customers in regulated and semi-regulated markets with a global presence extending to over 75+ countries with offices across India, U.S. and U.K. The Company has 7 manufacturing facilities out of which 6 are located in India and 1 in USA and has regulatory approvals from US FDA, EDQM, EU GMP, COFEPRIS, WHO GMP, TGA, K FDA, DEA, MCC and HALAL.

**Contacts:**

Krishna Raghunathan  
VP – Finance and Investor Relations  
040-30663573  
krishna.raghunathan@granulesindia.com

Chaitanya Tummala  
Company Secretary  
040-30663614  
chaitanya.tummala@granulesindia.com

**Safe Harbor**

*This document includes certain forward-looking statements. These statements are based on management's current expectations or beliefs and are subject to uncertainty and changes in circumstances. Actual results may vary materially from those expressed or implied by the statements herein due to changes in economic, business, competitive, technological and/or regulatory factors. Granules India Ltd., its directors and any of the affiliates or employee is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise.*